302333-80-8

Basic information

• Product Name: 4-Cyclopropyl-benzeneboronic acid
• Synonyms: 4-Cyclopropyl-phenylboronic acid
• CAS NO: 302333-80-8
• Molecular Formula: C₉H₁₁BO₂
• Molecular Weight: 162
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 302333-80-8.mol

Chemical Properties

• Boiling Point: 320.3 °C at 760 mmHg
• Flash Point: 147.5 °C
• Appearance: /
• Density: 1.17
• Storage Temp.: Room temperature.
• PKA: 8.74±0.10(Predicted)
• CAS DataBase Reference: 4-Cyclopropyl-benzeneboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyclopropyl-benzeneboronic acid(302333-80-8)
• EPA Substance Registry System: 4-Cyclopropyl-benzeneboronic acid(302333-80-8)

Safety Data

• Hazardous Substances Data: 302333-80-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropyl-benzeneboronic acid is used as a key intermediate in the synthesis of substituted indoles, which serve as PPAR-γ binding agents. PPAR-γ agonists are important in the treatment of type 2 diabetes and other metabolic disorders, highlighting the compound's significance in developing therapeutic agents for these conditions.
Additionally, 4-Cyclopropyl-benzeneboronic acid is utilized in the synthesis of thienopyrimidine bisphosphonate inhibitors. These inhibitors target farnesyl pyrophosphate synthase, an enzyme involved in the mevalonate pathway, and have potential applications in bone resorption treatment. This makes the compound a crucial component in the development of novel therapeutics for osteoporosis and related bone diseases.

Upstream product

• 1219741-94-2 2-(4-cyclopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 5467-74-3 4-Bromophenylboronic acid 
• 5419-55-6 Triisopropyl borate 
• 1124-14-7 1-bromo-4-cyclopropylbenzene 

Downstream Products

• 1394374-57-2 5-(4-cyclopropylphenyl)-4-methyl-3-(4-sulfamoylphenyl)thiophene-2-carboxylic acid 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE

The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

CD16A BINDING AGENTS AND USES THEREOF

Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.

Alkyl Carbagermatranes Enable Practical Palladium-Catalyzed sp2-sp3 Cross-Coupling

Pd-catalyzed cross-coupling reactions have achieved tremendous accomplishments in the past decades. However, C(sp3)-hybridized nucleophiles generally remain as challenging coupling partners due to their sluggish transmetalation compared to the C(sp2)-hybridized counterparts. While a single-electron-transfer-based strategy using C(sp3)-hybridized nucleophiles had made significant progress recently, fewer breakthroughs have been made concerning the traditional two-electron mechanism involving C(sp3)-hybridized nucleophiles. In this report, we present a series of unique alkyl carbagermatranes that were proven to be highly reactive in cross-coupling reactions with our newly developed electron-deficient phosphine ligands. Generally, secondary alkyl carbagermatranes show slightly lower, yet comparable activity to its Sn analogue. Meanwhile, primary alkyl carbagermatranes exhibit high activity, and they were also proved stable enough to be compatible with various reactions. Chiral secondary benzyl carbagermatrane gave the coupling product under base/additive-free conditions with its configuration fully inversed, suggesting that transmetalation was carried out in an "SE2(open) Inv" pathway, which is consistent with Hiyama's previous observation. Notably, the cross-coupling of primary alkyl carbagermatranes could be performed under base/additive-free conditions with excellent functional group tolerance and therefore may have potentially important applications such as stapled peptide synthesis.

TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(?- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS

The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D- glucopyranos-1 -yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a ph

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.